JOHNSON & JOHNSON (JNJ) Stock Overview
USA - NYSE:JNJ - US4781601046 - Common Stock
JNJ Key Statistics, Chart & Performance
The current stock price of JNJ is 191.17 USD. In the past month the price increased by 7.88%. In the past year, price increased by 15.78%.
JNJ Latest News, Press Relases and Analysis
JNJ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.18 | 782.32B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.11 | 263.02B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.58 | 252.03B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.69 | 251.60B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.09B | ||
| PFE | PFIZER INC | 7.19 | 138.67B | ||
| SNY | SANOFI-ADR | 11.1 | 119.32B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.48 | 88.77B | ||
| GSK | GSK PLC-SPON ADR | 9.77 | 88.11B | ||
| ZTS | ZOETIS INC | 22.85 | 62.98B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.5 | 43.77B | ||
| HLN | HALEON PLC-ADR | 18.76 | 40.94B |
Related stock screener links
About JNJ
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY 08933 US
CEO: A. Gorsky
Employees: 138100
Phone: 17325242455
JOHNSON & JOHNSON / JNJ FAQ
What is the stock price of JOHNSON & JOHNSON today?
The current stock price of JNJ is 191.17 USD. The price increased by 0.17% in the last trading session.
What is the ticker symbol for JOHNSON & JOHNSON stock?
The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is JNJ stock listed?
JNJ stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for JOHNSON & JOHNSON stock?
31 analysts have analysed JNJ and the average price target is 183.86 USD. This implies a price decrease of -3.82% is expected in the next year compared to the current price of 191.17. Check the JOHNSON & JOHNSON stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JOHNSON & JOHNSON worth?
JOHNSON & JOHNSON (JNJ) has a market capitalization of 460.40B USD. This makes JNJ a Mega Cap stock.
How many employees does JOHNSON & JOHNSON have?
JOHNSON & JOHNSON (JNJ) currently has 138100 employees.
What are the support and resistance levels for JOHNSON & JOHNSON (JNJ) stock?
JOHNSON & JOHNSON (JNJ) has a support level at 184.31 and a resistance level at 191.18. Check the full technical report for a detailed analysis of JNJ support and resistance levels.
Is JOHNSON & JOHNSON (JNJ) expected to grow?
The Revenue of JOHNSON & JOHNSON (JNJ) is expected to grow by 5.23% in the next year. Check the estimates tab for more information on the JNJ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JOHNSON & JOHNSON (JNJ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JNJ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JNJ, evaluating the profitability, health, valuation and growth aspects
- JOHNSON & JOHNSON (JNJ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JOHNSON & JOHNSON (JNJ) Sales and EPS estimates to see what analysts future expectations are.
- JOHNSON & JOHNSON (JNJ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JOHNSON & JOHNSON (JNJ) Insider and Institutional Ownership to learn about the owners and their transactions.
- JOHNSON & JOHNSON (JNJ) Stock Chart to make your own analysis
- JOHNSON & JOHNSON (JNJ) Latest news and press-releases to stay up to date.
Does JOHNSON & JOHNSON (JNJ) stock pay dividends?
JOHNSON & JOHNSON (JNJ) has a dividend yield of 2.72%. The yearly dividend amount is currently 4.91. Check the full fundamental report for a detailed analysis of JNJ dividend history, reliability and sustainability.
When does JOHNSON & JOHNSON (JNJ) report earnings?
JOHNSON & JOHNSON (JNJ) will report earnings on 2026-01-21, after the market close.
What is the Price/Earnings (PE) ratio of JOHNSON & JOHNSON (JNJ)?
The PE ratio for JOHNSON & JOHNSON (JNJ) is 18.42. This is based on the reported non-GAAP earnings per share of 10.38 and the current share price of 191.17 USD. Check the full fundamental report for a full analysis of the valuation metrics for JNJ.
What is the Short Interest ratio of JOHNSON & JOHNSON (JNJ) stock?
The outstanding short interest for JOHNSON & JOHNSON (JNJ) is 0.92% of its float. Check the ownership tab for more information on the JNJ short interest.
JNJ Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JNJ. When comparing the yearly performance of all stocks, JNJ is one of the better performing stocks in the market, outperforming 78.52% of all stocks.
JNJ Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to JNJ. JNJ has an excellent profitability rating, but there are some minor concerns on its financial health.
JNJ Financial Highlights
Over the last trailing twelve months JNJ reported a non-GAAP Earnings per Share(EPS) of 10.38. The EPS increased by 1.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25% | ||
| ROA | 11.72% | ||
| ROE | 28.88% | ||
| Debt/Equity | 0.61 |
JNJ Forecast & Estimates
31 analysts have analysed JNJ and the average price target is 183.86 USD. This implies a price decrease of -3.82% is expected in the next year compared to the current price of 191.17.
For the next year, analysts expect an EPS growth of 9.8% and a revenue growth 5.23% for JNJ